XML 13 R4.htm IDEA: XBRL DOCUMENT v3.22.2
Consolidated Statements of (Loss) Income and Comprehensive (Loss) Income (Unaudited) - USD ($)
shares in Thousands, $ in Thousands
 3 Months Ended 6 Months Ended
Jun. 30, 2022
Jun. 30, 2021
Jun. 30, 2022
Jun. 30, 2021
Revenues $ 32,126 $ 26,770 $ 62,499 $ 52,743
Cost of products sold 24,480 19,503 47,895 38,498
Gross profit 7,646 7,267 14,604 14,245
Operating expenses:        
Research and development 1,672 1,853 3,529 3,500
Selling, general and administrative 5,181 4,323 10,577 8,702
Total operating expenses 6,853 6,176 14,106 12,202
Operating income 793 1,091 498 2,043
Other expense (income):        
Interest and financing expense 177 55 311 111
Miscellaneous (62) (34) (79) (34)
Total other expense 115 21 232 77
Income before income tax provision 678 1,070 266 1,966
Income tax provision (benefit) 170 248 (81) 465
Net income 508 822 347 1,501
Net (loss) income attributable to non-controlling interest (4) 11 3 19
Net income attributable to Ultralife Corporation 512 811 344 1,482
Other comprehensive (loss) income:        
Foreign currency translation adjustments (1,262) 93 (1,498) 196
Comprehensive (loss) income attributable to Ultralife Corporation $ (750) $ 904 $ (1,154) $ 1,678
Net income per share attributable to Ultralife common stockholders – basic (in dollars per share) $ 0.03 $ 0.05 $ 0.02 $ 0.09
Net income per share attributable to Ultralife common stockholders – diluted (in dollars per share) $ 0.03 $ 0.05 $ 0.02 $ 0.09
Weighted average shares outstanding – basic (in shares) 16,129 16,019 16,116 15,997
Potential common shares (in shares) 20 241 25 197
Weighted average shares outstanding - diluted (in shares) 16,149 16,260 16,141 16,194